ANX005: Clinical Trials

2 trials of ANX005, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Terminated 1

Follow ANX005: new trials by email Literature Review of ANX005 trials Research Report on ANX005

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
ANX005, Intravenous immunoglobulin - Guillain-Barré Syndrome
Phase 1CompletedAnnexon, Inc.142020-01-292021-08-11
Single Dose Study of ANX005 in Healthy Volunteers
ANX005, IVIg, Placebos - Safety and Tolerability in Healthy Volunteers
Phase 1TerminatedAnnexon, Inc.272016-12-012020-08-20

Conditions studied

Guillain-Barre Syndrome (1)

Sponsors

Annexon, Inc. (2)

Countries

Australia (1)  ·  Bangladesh (1)  ·  Denmark (1)

Top investigators

Jason Lickliter, MBBS PhD (1)  ·  Sandy Calman, MD (1)

Results publications

PMID 29202623